Recombinant Human CHRNb1 protein

**Background of CHRNb1 Recombinant Protein**

The CHRNb1 (cholinergic receptor nicotinic beta 1 subunit) recombinant protein is a engineered form of the β1 subunit of the nicotinic acetylcholine receptor (nAChR), a ligand-gated ion channel critical for synaptic transmission in the nervous system and neuromuscular junctions. nAChRs are pentameric complexes composed of α and β subunits, with the β1 subunit primarily expressed in muscle-type receptors. These receptors mediate fast excitatory signaling by binding acetylcholine, leading to ion channel activation and membrane depolarization.

The β1 subunit plays a structural and functional role in receptor assembly, influencing ligand binding, ion conductance, and receptor stability. Recombinant CHRNb1 protein is produced using heterologous expression systems (e.g., mammalian cells, *E. coli*, or insect cells) to study its biochemical properties, interactions with other nAChR subunits (e.g., α1 in muscle receptors), and mechanisms underlying channel gating. It is often purified with affinity tags (e.g., His-tag) for experimental applications.

Research on CHRNb1 is pivotal in understanding neuromuscular disorders, such as congenital myasthenic syndromes (CMS), where mutations in *CHRNB1* impair receptor function, leading to muscle weakness. The recombinant protein also aids in drug discovery, enabling screening of therapeutics targeting neuromuscular signaling or neurodegenerative diseases like Alzheimer’s. Additionally, it serves as a tool to investigate the role of nAChRs in non-neuronal tissues, including immune regulation and cancer progression.

Overall, CHRNb1 recombinant protein bridges molecular studies and clinical applications, offering insights into receptor biology and disease mechanisms.